American Association for Cancer Research
ccr-23-0792_supplementary_figure_s1_suppsf1.pdf (357.59 kB)

Supplementary Figure S1 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer

Download (357.59 kB)
journal contribution
posted on 2023-12-15, 08:41 authored by Sophia C. Kamran, Yuzhen Zhou, Keisuke Otani, Michael Drumm, Yukako Otani, Shulin Wu, Chin-Lee Wu, Adam S. Feldman, Matthew Wszolek, Richard J. Lee, Philip J. Saylor, Jochen Lennerz, Eliezer Van Allen, Henning Willers, Theodore S. Hong, Yang Liu, Elai Davicioni, Ewan A. Gibb, William U. Shipley, Kent W. Mouw, Jason A. Efstathiou, David T. Miyamoto

Sample inclusion and analytic workflow.


Office of Extramural Research, National Institutes of Health (OER)

Radiation Oncology Institute (ROI)

George E. Safiol Foundation



There is an urgent need for biomarkers of radiation response in organ-sparing therapies. Bladder preservation with trimodality therapy (TMT), consisting of transurethral tumor resection followed by chemoradiation, is an alternative to radical cystectomy for muscle-invasive bladder cancer (MIBC), but molecular determinants of response are poorly understood. We characterized genomic and transcriptomic features correlated with long-term response in a single institution cohort of patients with MIBC homogeneously treated with TMT. Pretreatment tumors from 76 patients with MIBC underwent whole-exome sequencing; 67 underwent matched transcriptomic profiling. Molecular features were correlated with clinical outcomes including modified bladder-intact event-free survival (mBI-EFS), a composite endpoint that reflects long-term cancer control with bladder preservation. With a median follow-up of 74.6 months in alive patients, 37 patients had favorable long-term response to TMT while 39 had unfavorable long-term response. Tumor mutational burden was not associated with outcomes after TMT. DNA damage response gene alterations were associated with improved locoregional control and mBI-EFS. Of these alterations, somatic ERCC2 mutations stood out as significantly associated with favorable long-term outcomes; patients with ERCC2 mutations had significantly improved mBI-EFS [HR, 0.15; 95% confidence interval (CI), 0.06–0.37; P = 0.030] and improved BI-EFS, an endpoint that includes all-cause mortality (HR, 0.33; 95% CI, 0.15–0.68; P = 0.044). ERCC2 mutant bladder cancer cell lines were significantly more sensitive to concurrent cisplatin and radiation treatment in vitro than isogenic ERCC2 wild-type cells. Our data identify ERCC2 mutation as a candidate biomarker associated with sensitivity and long-term response to chemoradiation in MIBC. These findings warrant validation in independent cohorts.